Bitcoin steigt nach dem Halving wieder über 9‘000 Franken. Jetzt Bitcoin handeln! -w-
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
15.08.2018 13:00:00

Bio-Path Holdings Reports Second Quarter 2018 Financial Results

HOUSTON, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2018 and provided an update on recent corporate developments."During the second quarter we have continued to advance our corporate mission to develop RNAi nanoparticle drugs for cancer patients with high unmet medical need. Our ongoing Phase 2 clinical trial of prexigebersen for the treatment of acute myeloid leukemia (AML) is progressing according to plan. Earlier studies showed 47% of evaluable patients demonstrated some degree of response to prexigebersen in combination with LDAC in this patient population, which is supportive of our Phase 2 clinical development program. We are also enrolling a Phase 2 clinical trial of prexigebersen for the treatment of chronic myeloid leukemia (CML)." said Peter Nielsen, President and CEO of Bio-Path Holdings."In addition, we expect to be submitting an IND for BP1002, our next investigational drug candidate targeting Bcl-2 for the treatment of lymphoma and CLL, in 2018. To support these exciting efforts, we continue to gather the highest-caliber team of experts in cancer and biotechnology to guide Bio-Path's scientific and business strategy. As more of our drug candidates enter the clinic this year, we look forward to further exploring our novel therapeutics in the hope of providing better treatment options for patients most in need," continued Mr. Nielsen.Recent Corporate HighlightsReported interim results from Phase 2 study of prexigebersen in combination with LDAC for the treatment of AML. In April 2018, Bio-Path announced interim data from its ongoing Phase 2 clinical trial of its lead drug candidate prexigebersen. Of the 17 evaluable patients, 4 patients achieved complete responses, 1 patient achieved a leukemia free status, 1 patient had significantly reduced bone marrow blasts and 3 patients achieved stable disease. In total, 47% of the evaluable patients showed some form of response to the combination treatment, including 4 patients with complete remission (23%) and 4 patients with stable disease. Advanced Bio-Path's preclinical program studying prexigebersen in solid tumors. In April 2018, Bio-Path presented promising data at the American Association for Cancer Research Annual Meeting (AACR) 2018 on prexigebersen for the treatment of solid tumors in gynecologic malignancies. Prexigebersen decreased ...Full story available on Benzinga.com
Weiter zum vollständigen Artikel bei "Benzinga"